ZOMEDICA CORP (ZOM) Stock Price & Overview
NYSEARCA:ZOM • CA98980M1095
Current stock price
The current stock price of ZOM is 0.0973 USD. Today ZOM is down by -0.21%. In the past month the price decreased by -19.59%. In the past year, price decreased by -30.94%.
ZOM Key Statistics
- Market Cap
- 95.349M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.03
- Dividend Yield
- N/A
ZOM Stock Performance
ZOM Stock Chart
ZOM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ZOM. When comparing the yearly performance of all stocks, ZOM is a bad performer in the overall market: 85.19% of all stocks are doing better.
ZOM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZOM. No worries on liquidiy or solvency for ZOM as it has an excellent financial health rating, but there are worries on the profitability.
ZOM Earnings
On March 13, 2025 ZOM reported an EPS of -0.01 and a revenue of 7.00M. The company missed EPS expectations and missed revenue expectations (-20.3% surprise).
ZOM Forecast & Estimates
5 analysts have analysed ZOM and the average price target is 0.26 USD. This implies a price increase of 162.08% is expected in the next year compared to the current price of 0.0973.
For the next year, analysts expect an EPS growth of -110.78% and a revenue growth 10.67% for ZOM
ZOM Groups
Sector & Classification
ZOM Financial Highlights
Over the last trailing twelve months ZOM reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -57.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.05% | ||
| ROE | -30.66% | ||
| Debt/Equity | 0 |
ZOM Ownership
ZOM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 18.66 | 188.521B | ||
| ISRG | INTUITIVE SURGICAL INC | 46.96 | 169.656B | ||
| SYK | STRYKER CORP | 22.46 | 132.338B | ||
| BSX | BOSTON SCIENTIFIC CORP | 19.99 | 105.772B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.37 | 47.98B | ||
| IDXX | IDEXX LABORATORIES INC | 39.12 | 45.95B | ||
| BDX | BECTON DICKINSON AND CO | 11.48 | 45.012B | ||
| RMD | RESMED INC | 18.52 | 33.198B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.62 | 32.016B | ||
| DXCM | DEXCOM INC | 26.46 | 26.04B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.6 | 17.429B | ||
| HOLX | HOLOGIC INC | 15.35 | 16.777B | ||
| PODD | INSULET CORP | 35.36 | 16.212B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZOM
Company Profile
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.
Company Info
IPO: 2013-10-28
ZOMEDICA CORP
100 Phoenix Drive, Suite 125
Ann Arbor MICHIGAN 48108 US
CEO: Robert Cohen
Employees: 144
Phone: 17343692555
ZOMEDICA CORP / ZOM FAQ
Can you describe the business of ZOMEDICA CORP?
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.
Can you provide the latest stock price for ZOMEDICA CORP?
The current stock price of ZOM is 0.0973 USD. The price decreased by -0.21% in the last trading session.
Does ZOM stock pay dividends?
ZOM does not pay a dividend.
How is the ChartMill rating for ZOMEDICA CORP?
ZOM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about ZOMEDICA CORP (ZOM) stock?
5 analysts have analysed ZOM and the average price target is 0.26 USD. This implies a price increase of 162.08% is expected in the next year compared to the current price of 0.0973.
How many employees does ZOMEDICA CORP have?
ZOMEDICA CORP (ZOM) currently has 144 employees.